Scancell Holdings PLC (LSE:SCLP) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of private placement (PIPE Financing) Update: US$39.1M · US$0.1205 a share · Leerink Partners +2 Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co. Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs) Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones | Oct 9, 2026 | |
| Loan facility, partly convertible into Ordinary Shares, with warrants Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each… Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility) Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+ | Oct 9, 2026 | |
| Private placement of new Ordinary Shares Update: about US$12M · GBX 9 a share · Panmure Liberum Limited Dealers: Panmure Liberum Limited (lead) | Jul 24, 2026 | |
| Ordinary Shares Update: up to US$3M · GBX 9 a share | Jul 24, 2026 | |
| New ordinary shares (Retail Offer Shares) Closed: £1M raised · GBX 10.5 a share · Winterflood Securities Limited Dealers: Winterflood Securities Limited Use of proceeds: Further working capital and balance sheet strength | Dec 9, 2024 | US$1.28M |
| Private placement of new ordinary shares (Placing Shares) Made bigger: £10.3M · GBX 10.5 a share · Panmure Liberum Limited +1 Dealers: Panmure Liberum Limited (co-lead), WG Partners LLP (co-lead) Buyers: Redmile Group, LLC (28,571,428 Placing Shares); Vulpes Investment Management (10,476,190 Placing Shares) Insiders: Related parties Redmile and Vulpes, substantial shareholders, conditionally subscribing for 28,571,428 and 10,476,190 Placing Shares respectively Use of proceeds: Progress lead cancer vaccine SCIB1 and next generation iSCIB1+, and extend cash runway to H2 2026 | Dec 5, 2024 | US$13.13M |
| Private placement of new ordinary shares (Subscription Shares) Update: about £20,000 · GBX 10.5 a share Buyers: Sath Nirmalananthan (190,476 Ordinary Shares) Insiders: Director and CFO Sath Nirmalananthan conditionally subscribed for 190,476 Ordinary Shares | Dec 5, 2024 | US$25,395 |